Aurobindo Pharma has received approval of the US Food and Drug Administration (FDA) to market injection Eptifibatide, used in the treatment of acute coronary syndrome, in the American market.
The company has received final approval from the US health regulator (FDA) to manufacture and market Eptifibatide Injection, Aurobindo Pharma said in a filing to the BSE.
Eptifibatide Injection is used in the treatment of acute coronary syndrome.
Aurobindo now has 18 abbreviated new drug applications (ANDAs) approved out of Unit IV formulation facility in Hyderabad.
The company has a total of 222 ANDA approvals, including 10 from Aurolife Pharma LLC and 28 tentative approvals from FDA.